Boyan Georgiev, MD
Internal Medicine · Wilmington, NCNPI 1063457844
Payments from drug & device makers
Across 39 payments — averaging $71.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$935
- Novo Nordisk$443
- GSK$249
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
- Esperion Therapeutics, Inc.$225
- Galderma Laboratories, L.p.$125
- plus $565 from 9 others
What the payments were for
- Food & beverage$2,74099%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $935 |
| Novo Nordisk | 5 | $443 |
| GSK | 2 | $249 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $233 |
| Esperion Therapeutics, Inc. | 3 | $225 |
| Galderma Laboratories, L.p. | 1 | $125 |
| Amgen | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $117 |
| Corcept Therapeutics | 1 | $101 |
| Astellas Pharma US Inc | 6 | $72 |
| Pfizer | 2 | $68 |
| Lilly USA, LLC | 2 | $31 |
| Boehringer Ingelheim | 1 | $23 |
| Abbott | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,775 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 108 | $118,531 |
| OzempicSemaglutide | 61 | $87,030 |
| EliquisApixaban | 82 | $76,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $68,923 |
| TrulicityDulaglutide | 42 | $67,815 |
| JardianceEmpagliflozin | 45 | $55,262 |
| MounjaroTirzepatide | 38 | $49,958 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 105 | $34,125 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $26,021 |
| WegovySemaglutide | 16 | $25,909 |
| RybelsusSemaglutide | 13 | $25,533 |
| Repatha SureclickEvolocumab | 24 | $21,870 |
| EntrestoSacubitril/Valsartan | 11 | $20,223 |
| XareltoRivaroxaban | 13 | $18,454 |
| MyrbetriqMirabegron | 18 | $15,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $935 | $144,551125 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $443 | $138,47290 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $117,77380 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $249 | $106,437167 claims |
| PfizerEliquis | $68 | $76,58582 claims |
| Boehringer IngelheimJardiance | $23 | $55,26245 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $15,96718 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $117 | $12,05012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wilmington
- Brian WebsterWilmington$3.7M
- Hector SanchezWilmington$770K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.